A Phase 2 interventional study of Formoterol fumarate (6 μg) and Formoterol furmarate (20 μg) in Chronic Obstructive Pulmonary Disease - COPD, sponsored by AstraZeneca. Completed at 20 sites in United States. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-02-07.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 43rd largest by enrollment, is one of 9 that started in 2016, is one of 12 in phase 2, and was the 70th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 100th largest by enrollment of the 194 interventional ones that give a count, is one of 20 that started in 2016, is one of 54 in phase 2, and was the 187th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
This is a prospective, randomized, double-blind, 5-period incomplete unbalanced crossover, placebo and active comparator (open-label) controlled, multicenter clinical trial to assess the efficacy and safety of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label formoterol fumarate (20 μg BID and 40 μg single dose) administered as an inhalation solution via a standard jet nebulizer (with a mouthpiece) connected to an air compressor (Perforomist® Inhalation Solution). The drug product is an inhalation powder comprising of micronized aclidinium bromide and micronized formoterol fumarate with α-lactose monohydrate as the carrier, presented in a breathactuated device-metered dry-powder inhaler (DPI). It has been approved under the trademarks of Genuair® and/or Pressair® in some territories.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
Drug: Formoterol fumarate (6 μg)
Participants received formoterol fumarate 12 μg administered via Pressair BID.
Drug: Formoterol fumarate (12 μg)
Participants received formoterol fumarate 24 μg administered via Pressair BID.
Drug: Formoterol fumarate (12 μg)
Participants received placebo to formoterol fumarate administered via Pressair BID.
Drug: Placebo for formoterol fumarate
Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
Drug: Formoterol furmarate (20 μg)
Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
Drug: Formoterol fumarate (40 μg)
Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Also known as: Formoterol (Pressair®)
Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Also known as: Perforomist® Inhalation Solution
Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Also known as: Placebo (Pressair®)
Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Also known as: Formoterol (Pressair®)
Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Also known as: Perforomist® Inhalation Solution
Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Over the 12 h Period Immediately After Morning Study Drug Administration, AUC0-12/12h at Day 7 on Treatment
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate(20 μg). Pre-dose spirometry was performed before the morning daily dose at Day 1 and Day 7 of each treatment period. Two sets of measurements were performed during the hour preceding the scheduled morning study drug administration, allowing approximately 30 minutes between them. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.
Time frame: Day 7: 30 min, 1 to 4 hours, 6 hours, 9 hours and 12 hours post-dose
Change From Baseline in FEV1 AUC0-6/6h at Day 1 on Treatment
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg and 40 μg). 6-hour serial spirometry was performed at Day 1 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose.
Time frame: Day 1: zero time to 6 hours post-dose
Change From Baseline in FEV1 AUC0-6/6h at Day 7 on Treatment
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). 6-hour serial spirometry was performed at Day 7 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation
Time frame: Day 7: zero time to 6 hours post-dose
Change From Baseline in Morning Pre-dose (Trough) FEV1 at Day 7 on Treatment
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). Trough value was defined as the mean of the 2 pre-dose measurements on Day 7. If 1 of the 2 measurements was missing, the non-missing measurement was used as the trough value. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.
Time frame: At baseline and Day 7
This study was carried on 132 participants with moderate to severe chronic obstructive pulmonary disease (COPD) \& reversible airway disease in the United States of America (USA; 21 sites) \& were randomized to one of treatment sequences (each with 5 periods of different treatment, separated by wash-out period of 7 (+/1) days after treatment period).
| Milestone | Total Participants |
|---|---|
| Started | 132 |
| Formoterol fumarate (ff) 6 μg | 107 |
| Formoterol fumarate (ff) 12 μg | 121 |
| Formoterol fumarate (ff) 24 μg | 105 |
| Perforomist 20 μg | 118 |
| Perforomist 40 μg | 108 |
| Placebo (lactose monohydrate) | 38 |
| Completed | 106 |
| Not completed | 26 |
| Withdrew: Adverse event | 6 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Other | 10 |
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate(20 μg). Pre-dose spirometry was performed before the morning daily dose at Day 1 and Day 7 of each treatment period. Two sets of measurements were performed during the hour preceding the scheduled morning study drug administration, allowing approximately 30 minutes between them. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.
| Litre/Hour | Formoterol Fumarate 6 μg | Formoterol Fumarate (FF) 12 μg | Formoterol Fumarate (FF) 24 μg | Perforomist 20 μg | Placebo (Lactose Monohydrate) |
|---|---|---|---|---|---|
| Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Over the 12 h Period Immediately After Morning Study Drug Administration, AUC0-12/12h at Day 7 on Treatment | 0.108 (0.073 to 0.143) | 0.117 (0.082 to 0.151) | 0.161 (0.125 to 0.197) | 0.122 (0.087 to 0.156) | 0.000 (-0.055 to 0.054) |
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg and 40 μg). 6-hour serial spirometry was performed at Day 1 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose.
| Litre/Hour | Formoterol Fumarate 6 μg | Formoterol Fumarate (FF) 12 μg | Formoterol Fumarate (FF) 24 μg | Perforomist 20 μg | Perforomist 40 μg | Placebo (Lactose Monohydrate) |
|---|---|---|---|---|---|---|
| Change From Baseline in FEV1 AUC0-6/6h at Day 1 on Treatment | 0.111 (0.077 to 0.145) | 0.148 (0.115 to 0.182) | 0.205 (0.171 to 0.239) | 0.195 (0.162 to 0.229) | 0.246 (0.212 to 0.280) | -0.019 (-0.063 to 0.025) |
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). 6-hour serial spirometry was performed at Day 7 of each treatment period: spirometry was performed post-dose at 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours and 6 hours post-dose Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation
| Litre/Hour | Formoterol Fumarate 6 μg | Formoterol Fumarate (FF) 12 μg | Formoterol Fumarate (FF) 24 μg | Perforomist 20 μg | Placebo (Lactose Monohydrate) |
|---|---|---|---|---|---|
| Change From Baseline in FEV1 AUC0-6/6h at Day 7 on Treatment | 0.166 (0.127 to 0.205) | 0.177 (0.139 to 0.215) | 0.225 (0.186 to 0.265) | 0.186 (0.147 to 0.225) | 0.007 (-0.050 to 0.064) |
To assess the bronchodilation of 3 doses of formoterol fumarate (6 μg, 12 μg and 24 μg) BID administered via Pressair® compared to placebo and to open-label nebulised formoterol fumarate (20 μg). Trough value was defined as the mean of the 2 pre-dose measurements on Day 7. If 1 of the 2 measurements was missing, the non-missing measurement was used as the trough value. Note: Perforomist® 40 μg treatment periods lasted for 1 day only. Hence, was not included in the calculation.
| Litre | Formoterol Fumarate 6 μg | Formoterol Fumarate (FF) 12 μg | Formoterol Fumarate (FF) 24 μg | Perforomist 20 μg | Placebo (Lactose Monohydrate) |
|---|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose (Trough) FEV1 at Day 7 on Treatment | 0.077 (0.044 to 0.109) | 0.067 (0.035 to 0.098) | 0.102 (0.069 to 0.135) | 0.061 (0.029 to 0.092) | 0.002 (-0.059 to 0.063) |
Collected over From the time of signature of informed consent throughout the treatment period and including the follow-up period (i.e. 2 weeks after the last IP).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Formoterol Fumarate 6 μg | 0/107 (0%) | 1/107 (0.9%) | 3/107 (2.8%) |
| Formoterol Fumarate (FF) 12 μg | 1/121 (0.8%) | 2/121 (1.7%) | 4/121 (3.3%) |
| Formoterol Fumarate (FF) 24 μg | 0/105 (0%) | 0/105 (0%) | 1/105 (1%) |
| Perforomist 20 μg | 0/118 (0%) | 0/118 (0%) | 7/118 (5.9%) |
| Perforomist 40 μg | 0/109 (0%) | 1/109 (0.9%) | 0/109 (0%) |
| Placebo (Lactose Monohydrate) | 0/38 (0%) | 1/38 (2.6%) | 3/38 (7.9%) |
| Event | Formoterol Fumarate 6 μg | Formoterol Fumarate (FF) 12 μg | Formoterol Fumarate (FF) 24 μg | Perforomist 20 μg | Perforomist 40 μg | Placebo (Lactose Monohydrate) |
|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/107 | 0/121 | 0/105 | 0/118 | 0/109 | 1/38 |
| Multiple injuriesInjury, poisoning and procedural complications | 1/107 | 0/121 | 0/105 | 0/118 | 0/109 | 0/38 |
| Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/107 | 0/121 | 0/105 | 0/118 | 1/109 | 0/38 |
| Myocardial infarctionCardiac disorders | 0/107 | 1/121 | 0/105 | 0/118 | 0/109 | 0/38 |
| Vascular stent occlusionGeneral disorders | 0/107 | 1/121 | 0/105 | 0/118 | 0/109 | 0/38 |
| Event | Formoterol Fumarate 6 μg | Formoterol Fumarate (FF) 12 μg | Formoterol Fumarate (FF) 24 μg | Perforomist 20 μg | Perforomist 40 μg | Placebo (Lactose Monohydrate) |
|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/107 | 0/121 | 0/105 | 0/118 | 0/109 | 3/38 |
| HeadacheNervous system disorders | 0/107 | 3/121 | 1/105 | 2/118 | 0/109 | 0/38 |
| Urinary tract infectionInfections and infestations | 2/107 | 1/121 | 0/105 | 1/118 | 0/109 | 0/38 |
| Upper respiratory tract infectionInfections and infestations | 1/107 | 0/121 | 0/105 | 2/118 | 0/109 | 0/38 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/107 | 0/121 | 0/105 | 2/118 | 0/109 | 0/38 |
The ITT analysis set: Consisted of all randomized participants who received at least 1 dose of investigational product (IP) and had a baseline FEV1 value and at least 1 post-baseline FEV1 measurement, regardless of a participant's adherence to the randomized treatment.
| Age, Continuous(Years) | Overall Study Total |
|---|---|
| Mean | 62.3 ± 7.5 |
| Age, Customized(Participants) | Overall Study Total |
|---|---|
| <50 years | 5 |
| ≥50 to <65 years | 78 |
| ≥65 years | 48 |
| Sex: Female, Male(Participants) | Overall Study Total |
|---|---|
| Female | 66 |
| Male | 65 |
Ran from Jun 2016 to primary completion in Dec 2016, 5 months.
Results were first posted in Feb 2018, 1 year 2 months after primary completion.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 5 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →